• Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)

• Clinical diagnosis of T1D

• Diabetes duration diagnosed ≥ 12 months ago

• HbA1c ≤10% at screening and within the past 90 days

• Stable reported insulin dosing in the past 90 days (within 15%)

• Stable reported BMI in the past 90 days (within 5%)

• Ability to provide written informed consent before any trial-related activities

• Use of real-time continuous glucose monitoring and planned continued use

• Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contraception: oral, injectable or implantable, Placement of an intrauterine device or intrauterine system, Bilateral tubal occlusion (fallopian tubes are blocked), Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate), or Complete sexual abstinence from male-female sex)

• Stated willingness to comply with all study procedures, medication regimen, and availability for the duration of the study

• Participants cannot be randomized if any laboratory safety parameter at screening is outside the below extended laboratory ranges. For randomization, participants should have

‣ Creatinine \<1.0mg

⁃ Triglycerides (\<400 mg/dl)

⁃ ALT \<3.5 times the upper normal limit (UNL)